Tarsus Pharmaceuticals Inc [TARS] stock prices are up 0.13% to $54.21 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TARS shares have gain 13.29% over the last week, with a monthly amount glided 30.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On November 20, 2023, Goldman initiated with a Neutral rating and assigned a price target of $19 on the stock. William Blair started tracking the stock assigning a Outperform rating and suggested a price target of $44 on July 18, 2023. Guggenheim initiated its recommendation with a Buy. Barclays started tracking with a Overweight rating for this stock on August 01, 2022, and assigned it a price target of $40. In a note dated December 21, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $40 on this stock.
The stock price of Tarsus Pharmaceuticals Inc [TARS] has been fluctuating between $24.95 and $57.28 over the past year. Currently, Wall Street analysts expect the stock to reach $71 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $54.21 at the most recent close of the market. An investor can expect a potential return of 30.97% based on the average TARS price forecast.
Analyzing the TARS fundamentals
The Tarsus Pharmaceuticals Inc [NASDAQ:TARS] reported sales of 295.52M for trailing twelve months, representing a surge of 151.54%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.33%, Pretax Profit Margin comes in at -0.31%, and Net Profit Margin reading is -0.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.32 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.24 points at the first support level, and at 52.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 55.13, and for the 2nd resistance point, it is at 56.04.
Ratios To Look Out For
It’s worth pointing out that Tarsus Pharmaceuticals Inc [NASDAQ:TARS]’s Current Ratio is 5.26. As well, the Quick Ratio is 5.21, while the Cash Ratio is 1.07. Considering the valuation of this stock, the price to sales ratio is 7.74, the price to book ratio is 6.88.
Transactions by insiders
Recent insider trading involved Azamian Bobak R., President/CEO and Board Chair, that happened on Aug 11 ’25 when 6000.0 shares were sold. Officer, Azamian Bobak R. completed a deal on Aug 11 ’25 to buy 6000.0 shares. Meanwhile, Farrow Jeffrey S sold 13608.0 shares on Jun 17 ’25.
